company background image
VAPO

Vapotherm NYSE:VAPO Stock Report

Last Price

US$2.69

Market Cap

US$71.5m

7D

-4.9%

1Y

-88.6%

Updated

29 Jun, 2022

Data

Company Financials +
VAPO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

VAPO Stock Overview

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally.

Vapotherm Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vapotherm
Historical stock prices
Current Share PriceUS$2.69
52 Week HighUS$31.87
52 Week LowUS$2.46
Beta-0.36
1 Month Change-19.94%
3 Month Change-80.65%
1 Year Change-88.62%
3 Year Change-87.67%
5 Year Changen/a
Change since IPO-83.19%

Recent News & Updates

May 11

Vapotherm: Out Of Air

Vapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time. With revenues down to much lower levels and losses being very substantial, there are no (quick) fixes in sight.

Shareholder Returns

VAPOUS Medical EquipmentUS Market
7D-4.9%3.4%1.6%
1Y-88.6%-24.5%-20.8%

Return vs Industry: VAPO underperformed the US Medical Equipment industry which returned -25.7% over the past year.

Return vs Market: VAPO underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is VAPO's price volatile compared to industry and market?
VAPO volatility
VAPO Average Weekly Movement17.7%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: VAPO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: VAPO's weekly volatility has increased from 11% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993510Joe Armyhttps://www.vapotherm.com

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors.

Vapotherm Fundamentals Summary

How do Vapotherm's earnings and revenue compare to its market cap?
VAPO fundamental statistics
Market CapUS$71.46m
Earnings (TTM)-US$72.33m
Revenue (TTM)US$102.61m

0.7x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VAPO income statement (TTM)
RevenueUS$102.61m
Cost of RevenueUS$58.69m
Gross ProfitUS$43.91m
Other ExpensesUS$116.24m
Earnings-US$72.33m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.72
Gross Margin42.80%
Net Profit Margin-70.49%
Debt/Equity Ratio178.9%

How did VAPO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is VAPO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VAPO?

Other financial metrics that can be useful for relative valuation.

VAPO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VAPO's PS Ratio compare to its peers?

VAPO PS Ratio vs Peers
The above table shows the PS ratio for VAPO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average73.3x
OMWS Omnia Wellness
280.3xn/aUS$85.7m
CTSO Cytosorbents
2.4x30.2%US$98.0m
DRIO DarioHealth
4.9x35.6%US$121.6m
AXDX Accelerate Diagnostics
5.6x18.0%US$68.6m
VAPO Vapotherm
0.7x13.2%US$71.5m

Price-To-Sales vs Peers: VAPO is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (73.3x).


Price to Earnings Ratio vs Industry

How does VAPO's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: VAPO is good value based on its Price-To-Sales Ratio (0.7x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is VAPO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VAPO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: VAPO is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).


Share Price vs Fair Value

What is the Fair Price of VAPO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VAPO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VAPO's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VAPO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Vapotherm forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


32.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VAPO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VAPO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VAPO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VAPO's revenue (13.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: VAPO's revenue (13.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VAPO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Vapotherm performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-14.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VAPO is currently unprofitable.

Growing Profit Margin: VAPO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VAPO is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.

Accelerating Growth: Unable to compare VAPO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VAPO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: VAPO has a negative Return on Equity (-134.12%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Vapotherm's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: VAPO's short term assets ($125.8M) exceed its short term liabilities ($23.4M).

Long Term Liabilities: VAPO's short term assets ($125.8M) exceed its long term liabilities ($103.2M).


Debt to Equity History and Analysis

Debt Level: VAPO's net debt to equity ratio (43.7%) is considered high.

Reducing Debt: VAPO's debt to equity ratio has increased from 96.5% to 178.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VAPO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VAPO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.7% each year


Discover healthy companies

Dividend

What is Vapotherm current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate VAPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VAPO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VAPO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VAPO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VAPO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Joe Army (57 yo)

10yrs

Tenure

US$3,442,120

Compensation

Mr. Joseph F. Army, also known as Joe, CPA has been the Chief Executive Officer and President of Vapotherm, Inc. since June 26, 2012. Mr. Army served as the Chief Executive Officer and President of Salient...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD3.44M) is above average for companies of similar size in the US market ($USD759.63K).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VAPO's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: VAPO's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VAPO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

Vapotherm, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Vapotherm, Inc.
  • Ticker: VAPO
  • Exchange: NYSE
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$71.456m
  • Shares outstanding: 26.56m
  • Website: https://www.vapotherm.com

Number of Employees


Location

  • Vapotherm, Inc.
  • 100 Domain Drive
  • Exeter
  • New Hampshire
  • 3833
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.